Anavex Life Sciences Corp expected to post a loss of 15 cents a share - Earnings Preview

Anavex Life Sciences

09/05/2025 16:58

Anavex Life Sciences Corp AVXL.OQ AVXL.O is expected to show no change in quarterly revenue when it reports  results on May 13 for the period ending March 31 2025

‚ÄčLSEG's mean analyst estimate for Anavex Life Sciences Corp is for a loss of 15 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Anavex Life Sciences Corp is $41.45‚Äč, above‚Äč its last closing price of $8.56. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.17
-0.17
-0.14
Beat
17.6
Sep. 30 2024
-0.16
-0.14
Beat
14.3
Jun. 30 2024
-0.16
-0.16
-0.14
Beat
12.5‚Äč
Mar. 31 2024
-0.11
-0.11
-0.13
Missed
-18.2
‚Äč‚ÄčDec. 31 2023
-0.14
-0.14
-0.11
Beat
24.1
Sep. 30 2023
-0.14
-0.15
-0.12
Beat
18.2‚Äč
Jun. 30 2023
-0.17
-0.17
-0.14
Beat
16
Mar. 31 2023
-0.19
-0.19
-0.17
Beat
8.9

This summary was machine generated May 9 at 15:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)